Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001654954-18-004465
Filing Date
2018-04-27
Accepted
2018-04-27 17:16:41
Documents
3
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K azrx10ka_dec312017.htm 10-K/A 450501
2 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF azrx_313.htm EX-31.3 6678
3 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF azrx_314.htm EX-31.4 6837
  Complete submission text file 0001654954-18-004465.txt   465110
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: 10-K/A | Act: 34 | File No.: 001-37853 | Film No.: 18785508
SIC: 2834 Pharmaceutical Preparations